In an attempt to broaden its immunology pipeline, Sanofi has agreed to acquire Dren Bio’s targeted bispecific myeloid cell engager, DR-0201. Through the deal, which involves a US$600 M upfront payment and up to US$1.3 B in milestones, Sanofi picks up the potential first-in-class CD20-directed bispecific antibody that has shown robust B-cell depletion in preclinical and early clinical studies for haematologic neoplasms and a range of autoimmune diseases. Following the acquisition, Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics.